From vitamin k antagonists to liver international normalized ratio: A historical journey and critical perspective

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 8, 2014, Pages 845-851

  Gatt, Alexander ^a   Chen, Dong ^b   Pruthi, Rajiv K ^b   Kamath, Patrick S ^c   Leise, Michael D ^c   Ashrani, Aneel A ^b   Nichols, William L ^b   He, Rong ^b,c  

^a UNIVERSITY OF MALTA   (Malta)

^b Department of Health Sciences Research   (United States)

^c MAYO CLINIC   (United States)

Author keywords

INR; ISI; liver disease; liver transplant; MELD score; prothrombin time; PT; vitamin K antagonist; warfarin

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; END STAGE LIVER DISEASE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER; MODEL FOR END STAGE LIVER DISEASE SCORE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; HISTORY; LIVER DISEASES; PROTHROMBIN TIME;

ANIMALS; ANTICOAGULANTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASES; PROTHROMBIN TIME; VITAMIN K; WARFARIN;

EID: 84928547800     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395160     Document Type: Article

References (44)

1. Schofield F. W. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J Am Vet Med Assoc: 1924; 64 553 575
2. Campbell A. H., Smith W. K., Roberts W. L., Link K. P. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem: 1941; 138 21 33
3. Allen E. V., Barker N. W., Waugh J. M. A preparation from spoiled sweet clover (3,3′-methylene-bis-[4-hydroxycoumarin]) which prolongs coagulation and prothrombin time of the blood: a clinical study. JAMA: 1942; 120 13 1015 1021
4. Link K. P. The discovery of dicumarol and its sequels. Circulation: 1959; 19 1 97 107
5. Quick A. J. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem: 1935; 109 73 74
6. Quick A. J. The development and use of the prothrombin tests. Circulation: 1959; 19 1 92 96
7. Sise H. S., Lavelle S. M., Adamis D., Becker R. Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N Engl J Med: 1958; 259 6 266 271
8. Verstraete M., Clark P. A., Wright I. S. Use of different tissue thromboplastins in the control of anticoagulant therapy. Circulation: 1957; 16 2 213 226
9. Poller L., Taberner D. A. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol: 1982; 51 3 479 485
10. Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost: 2004; 2 6 849 860
11. Smith R. E. The INR: a perspective. Semin Thromb Hemost: 1997; 23 6 547 549
12. Kirkwood T. B. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost: 1983; 49 3 238 244
13. Organisation W. H. Requirements for thromboplastins and plasma used to control oral anticoagulant therapy (requirements for biological substances no.30, revised 1982). WHO Expert Committee on Biological Standardization Thirty-Third Report Annexure 3. WHO Technical Report Series, No. 687. Geneva, Switzerland World Health Organization: 1983
14. Tange J. I., Grill D., Koch C. D., et al. Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost: 2014; 40 1 115 120
15. Favaloro E. J., Adcock D. M. Standardization of the INR: how good is your laboratory's INR and can it be improved? Semin Thromb Hemost: 2008; 34 7 593 603
16. WHO Expert Committee on Biological Standardization WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser: 1999; 889 i vi, 1-111
17. Shahangian S., Labeau K. M., Howerton D. A. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem: 2006; 52 5 793 794
18. Kamath P. S., Wiesner R. H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology: 2001; 33 2 464 470
19. Wiesner R., Edwards E., Freeman R., et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology: 2003; 124 1 91 96
20. Jung G. E., Encke J., Schmidt J., Rahmel A. [Model for end-stage liver disease. New basis of allocation for liver transplantations]. Chirurg: 2008; 79 2 157 163
21. Trotter J. F., Brimhall B., Arjal R., Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl: 2004; 10 8 995 1000
22. Porte R. J., Lisman T., Tripodi A., Caldwell S. H., Trotter J. F.; Coagulation in Liver Disease Study Group. The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant: 2010; 10 6 1349 1353
23. Trotter J. F., Olson J., Lefkowitz J., Smith A. D., Arjal R., Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant: 2007; 7 6 1624 1628
24. Gatt A. Global Assays of Coagulation in Anticoagulation, Thrombotic Disorders and Liver Disease. Sheffield, UK University of Sheffield: 2012
25. Gatt A., Riddell A., Calvaruso V., Tuddenham E. G., Makris M., Burroughs A. K. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost: 2010; 8 9 1994 2000
26. Tripodi A., Salerno F., Chantarangkul V., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology: 2005; 41 3 553 558
27. Tripodi A., Mannucci P. M. The coagulopathy of chronic liver disease. N Engl J Med: 2011; 365 2 147 156
28. Wada H., Usui M., Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost: 2008; 34 8 772 778
29. Francis J. L., Armstrong D. J. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol: 1982; 35 6 667 672
30. Tripodi A., Chantarangkul V., Primignani M., et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology: 2007; 46 2 520 527
31. Bellest L., Eschwège V., Poupon R., Chazouillères O., Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology: 2007; 46 2 528 534
32. Sermon A. M., Smith J. M., Maclean R., Kitchen S. An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents. Thromb Haemost: 2010; 103 4 757 765
33. Riddell A. F., Calvaruso V., Tuddenham E. G., Burroughs A., Gatt A. A pragmatic approach for the measurement of the INR in liver patients. J Thromb Haemost: 2009; 7 abstract 10 6
34. Tripodi A., Chantarangkul V., Primignani M., et al. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. J Hepatol: 2009; 51 2 288 295
35. Tripodi A. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. Hepatology: 2008; 47 4 1423 1424, author reply 1424
36. Marlar R. A. Determining the model for end-stage liver disease with better accuracy: neutralizing the international normalized ratio pitfalls. Hepatology: 2007; 46 2 295 296
37. Tripodi A., Baglin T., Robert A., Kitchen S., Lisman T., Trotter J. F.; Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. J Thromb Haemost: 2010; 8 6 1410 1412
38. Heuman D. M., Mihas A. A., Habib A., et al. MELD-XI: a rational approach to sickest first liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl: 2007; 13 1 30 37
39. Izumi S., Langley P. G., Wendon J., et al. Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure. Hepatology: 1996; 23 6 1507 1511
40. Leise M. D., Kim W. R., Kremers W. K., Larson J. J., Benson J. T., Therneau T. M. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology: 2011; 140 7 1952 1960
41. Owren P. A. Thrombotest. A new method for controlling anticoagulant therapy. Lancet: 1959; 2 7106 754 758
42. Magnusson M., Sten-Linder M., Bergquist A., et al. The international normalized ratio according to Owren in liver disease: interlaboratory assessment and determination of international sensitivity index. Thromb Res: 2013; 132 3 346 351
43. Gatt A., Burroughs A. K. The Owren INR in liver disease: a way towards standardisation? Thromb Res: 2013; 132 3 327 328
44. Kim W. R., Biggins S. W., Kremers W. K., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med: 2008; 359 10 1018 1026